Table 1.
Characteristics of patients treated with infliximab. * Other cancer types are HNSCC, Uveal melanoma, esophageal-gastric adenocarcinoma, urothelial carcinoma, pancreas, breast. ** Participating in clinical trials randomizing to receive combination versus ICI monotherapy. *** Participating in clinical trials randomizing to receive either anti-CTLA-4 or anti-PD1. **** Other toxicities are erythema multiform dermatitis, arthritis, type 1 diabetes, Stevens–Johnson syndrome, rash, bullous pemphigoid, enteritis, and cytokine release syndrome. NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma.
| N | 56 |
|---|---|
| Age—mean (SD) | 62.9 (SD 12) |
| Gender—n (%) | |
| Female | 18 (32%) |
| Male | 38 (68%) |
| Type of Cancer—n (%) | |
| Melanoma | 35 (62%) |
| NSCLC | 4 (7%) |
| RCC | 5 (9%) |
| Others * | 12 (22%) |
| Combination therapy at time of toxicity—n (%) | |
| No | 27 (48%) |
| Yes | 25 (45%) |
| Unknown ** | 4 (7%) |
| ICI monotherapy—n (%) | |
| Anti-CTLA4 | 11 (40.8%) |
| Anti-PD1 | 13 (48.1%) |
| Off ICI | 1 (3.7%) |
| Unknown *** | 2 (7.4%) |
| ICI Combination—n (%) | |
| Anti-CTLA4 + Anti-PD1 | 19 (76%) |
| Other | 6 (24%) |
| Type of Toxicity—n (%) | |
| Colitis | 37 (66.1%) |
| Hepatitis | 1 (1.8%) |
| Myocarditis | 2 (3.6%) |
| Pneumonitis | 6 (10.7%) |
| Others **** | 10 (17.8%) |
| Multiple toxicities at Onset—n (%) | |
| No | 45 (80%) |
| Yes | 11 (20%) |
| Line of ICI treatment—n (%) | |
| Adjuvant | 5 (9%) |
| 1st | 29 (52%) |
| 2nd | 13 (23%) |
| 3rd | 6 (11%) |
| ≥4th | 3 (5%) |
| Best response to ICI that induced toxicity—n (%) | |
| CR | 4 (7%) |
| PR | 12 (21%) |
| SD | 13 (23%) |
| PD | 22 (39%) |
| N/A | 5 (9%) |
| Outcome of toxicity—n (%) | |
| Not resolved | 13 (24%) |
| Resolved | 42 (76%) |
| Missing | 1 |
| Resumed ICI—n (%) | |
| No | 46 (82%) |
| Yes | 10 (18%) |
| Recrudescence of Toxicity—n (%) | |
| No | 38 (69%) |
| Yes | 17 (31%) |